Skip to content

Sign in Start free

Create your free account

Loading your page…

We care for the people who care.

No ads. No selling of your data. No third-party trackers.

Apps

Prognia
Ward
Suture
Osler

Library

Guidelines
Medicines
Articles
Calculators
Explore decks
Blog

Prognia

About
Pricing
Contact

Support us

Founders Wall

© 2026 Prognia · Amsterdam, the NetherlandsPrivacy TermsExchangeRate-API

Medicines · US (FDA)
Antivirals

FDA 2017

Nucleoside and nucleotide reverse transcriptase inhibitors

Lamivudine and Zidovudine

Approved 5 May 2017OralTablet

The FDA lists this product in 13 strengths and forms.

Official labelAsk Osler about it

On this page

Composition
Strengths and forms
Official product information

The table holds no label text for this product yet, only the facts beside it. The official product information has the full text.

Composition

Active ingredients: LAMIVUDINE 150MG; ZIDOVUDINE 300MG

Strengths and forms

The FDA lists each strength of a product separately; these pages share one label.

LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletThis page
LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletANDA079124-001 · Prescription
LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletANDA090246-001 · Discontinued
LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletANDA206375-001 · Prescription
LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletANDA079079-001 · Discontinued
LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletANDA079081-001 · Discontinued
LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletANDA079128-001 · Prescription
LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletANDA090679-001 · Prescription
LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletANDA202418-001 · Discontinued
LAMIVUDINE 150MG; ZIDOVUDINE 300MG · Tablet

More in antivirals

Idvynsodoravirine · Tablet
Rilpivirine HydrochlorideTablet

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

ANDA077411-001 · Prescription

LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletNDA022018-001 · Discontinued

LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletANDA203259-001 · Prescription

LAMIVUDINE 150MG; ZIDOVUDINE 300MG · TabletANDA204005-001 · Discontinued

Official product information

Drugs@FDA lists the approved labels, letters and reviews for application ANDA077558.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Brand name: Lamivudine and Zidovudine
Active substance: lamivudine
Drug class: Nucleoside and nucleotide reverse transcriptase inhibitors, Antivirals for treatment of HIV infections, combinations
Group: Antivirals
Route: Oral
Dosage form: Tablet
Applicant: Aurobindo Pharma
Status: Prescription
FDA approval: 5 May 2017
Application: ANDA077558-001
RxCUI: 214671

Guidelines

Guidelines in infectious diseases1,342 guidelines in the library

FDA 2026

RilpivirineTablet

FDA 2025Emtricitabine and Tenofovir Alafenamideemtricitabine, tenofovir alafenamide · Tablet

FDA 2025Abacavir, Dolutegravir, LamivudineTablet

FDA 2025Bictegravir, Emtricitabine and Tenofovir AlafenamideTablet

FDA 2025Dolutegravir Sodium and Abacavir Sulfate and Lamivudineabacavir || dolutegravir || lamivudine · Tablet

FDA 2025Emtricitabine, Rilpivirine and Tenofovir Disoproxil Fumarateemtricitabine · Tablet

FDA 2024Emtricitabine and Tenofovir Alafenamide Fumarateemtricitabine · Tablet

FDA 2023Abacavir Sulfate and Lamivudineabacavir sulfate · Tablet, for suspension

FDA 2023PodofiloxGel

FDA 2023Dolutegravir; Emtricitabine; Tenofovir Alafenamidedolutegravir · Tablet

FDA 2023Dolutegravir; Rilpivirinedolutegravir · Tablet

FDA 2022PenciclovirCream

FDA 2022Trifluridine; Tipiraciltrifluridine · Tablet

FDA 2022Abacavir; Dolutegravir; Lamivudineabacavir · Tablet

FDA 2022Triumeq PDabacavir sulfate · Tablet, for suspension

FDA 2021Livtencitymaribavir · Tablet